Compugen is a therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet medical needs in the fields of immunology and oncology. To discover drug candidates, the company utilizes a broad and continuously growing integrated infrastructure of proprietary platforms, algorithms, machine learning systems, and other computational biology capabilities.
The company announced today the discovery and initial validation of two new drug target candidates for monoclonal antibody cancer therapy. These two candidates have been shown to be expressed in multiple types of tumors and were demonstrated to have an immunomodulatory activity in affecting both innate and adaptive immune response. This provides the potential for an efficient and targeted approach in cancer treatment.
In recent in vitro studies, both of these immune checkpoint molecules have shown distinct activity inhibiting two key subtypes of immune cells, Natural Killer cells and T cells. These important immune cell subtypes act to recognize and kill tumor cells and have key roles in the immune system’s response to tumor development.
Antibodies directed at and blocking each of these immune checkpoints could remove their inhibitory effect on T cells and NK cells. This will enhance the anti-tumor activity of these pivotal immune cell subsets, promoting efficient cancer immunotherapy and long-lived tumor destruction. The two Compugen-discovered molecules indicate enhanced expression in a number of cancers including lung, ovarian, breast, colorectal, gastric, and liver cancer.
For additional information about Compugen and its entire drug pipeline, please visit www.cgen.com
Let us hear your thoughts below: